{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:44:43Z","timestamp":1790138683115,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,7,6]]},"DOI":"10.1038\/s41416-021-01332-x","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T09:07:14Z","timestamp":1617959234000},"page":"55-64","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin"],"prefix":"10.1038","volume":"125","author":[{"given":"Mawar","family":"Karsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Kosciolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Bongers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mariana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Failes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Gifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula R.","family":"Kees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence C.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi S.","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg M.","family":"Arndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray D.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2741-3852","authenticated-orcid":false,"given":"Michelle J.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaartje","family":"Somers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"1332_CR1","doi-asserted-by":"crossref","unstructured":"Pui, C. H. in Childhood Leukemias. 3rd edn, Chapter 13, Acute lymphoblastic leukemia, 332\u2013366 (Cambridge University Press, 2012).","DOI":"10.1017\/CBO9780511977633.014"},{"key":"1332_CR2","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","volume":"33","author":"CH Pui","year":"2015","unstructured":"Pui, C. H., Yang, J. J., Hunger, S. P., Pieters, R., Schrappe, M., Biondi, A. et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J. Clin. Oncol. 33, 2938\u20132948 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1332_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","volume":"10","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith, E., Mullighan, C. G., Onciu, M., Behm, F. G., Raimondi, S. C., Pei, D. et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 10, 147\u2013156 (2009).","journal-title":"Lancet Oncol."},{"key":"1332_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejca.2017.06.012","volume":"82","author":"JM Boer","year":"2017","unstructured":"Boer, J. M. & den Boer, M. L. BCR-ABL1-like acute lymphoblastic leukaemia: from bench to bedside. Eur. J. Cancer 82, 203\u2013218 (2017).","journal-title":"Eur. J. Cancer"},{"key":"1332_CR5","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/pbc.20352","volume":"44","author":"MJ Adams","year":"2005","unstructured":"Adams, M. J. & Lipshultz, S. E. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr. Blood Cancer 44, 600\u2013606 (2005).","journal-title":"Pediatr. Blood Cancer"},{"key":"1332_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1586\/ehm.11.8","volume":"4","author":"KK Ness","year":"2011","unstructured":"Ness, K. K., Armenian, S. H., Kadan-Lottick, N. & Gurney, J. G. Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health. Expert Rev. Hematol. 4, 185\u2013197 (2011).","journal-title":"Expert Rev. Hematol."},{"key":"1332_CR7","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1200\/JCO.2008.20.1541","volume":"27","author":"DM Green","year":"2009","unstructured":"Green, D. M., Kawashima, T., Stovall, M., Leisenring, W., Sklar, C. A., Mertens, A. C. et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J. Clin. Oncol. 27, 2677\u20132685 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1332_CR8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1200\/JCO.2009.24.9037","volume":"28","author":"DM Green","year":"2010","unstructured":"Green, D. M., Kawashima, T., Stovall, M., Leisenring, W., Sklar, C. A., Mertens, A. C. et al. Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J. Clin. Oncol. 28, 332\u2013339 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1332_CR9","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1182\/blood-2007-10-117150","volume":"111","author":"R Mody","year":"2008","unstructured":"Mody, R., Li, S., Dover, D. C., Sallan, S., Leisenring, W., Oeffinger, K. C. et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood 111, 5515\u20135523 (2008).","journal-title":"Blood"},{"key":"1332_CR10","doi-asserted-by":"crossref","unstructured":"Robison, L. L. Late effects of acute lymphoblastic leukemia therapy in patients diagnosed at 0\u201320 years of age. Hematology Am. Soc. Hematol. Educ. Program 2011, 238\u2013242 (2011).","DOI":"10.1182\/asheducation-2011.1.238"},{"key":"1332_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","volume":"370","author":"R Pieters","year":"2007","unstructured":"Pieters, R., Schrappe, M., De Lorenzo, P., Hann, I., De Rossi, G., Felice, M. et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 370, 240\u2013250 (2007).","journal-title":"Lancet"},{"key":"1332_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.17","volume":"4","author":"RS Kotecha","year":"2014","unstructured":"Kotecha, R. S., Gottardo, N. G., Kees, U. R. & Cole, C. H. The evolution of clinical trials for infant acute lymphoblastic leukemia. Blood Cancer J. 4, e200 (2014).","journal-title":"Blood Cancer J."},{"key":"1332_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/gm326","volume":"4","author":"YY Li","year":"2012","unstructured":"Li, Y. Y. & Jones, S. J. Drug repositioning for personalized medicine. Genome Med. 4, 27 (2012).","journal-title":"Genome Med."},{"key":"1332_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Disco. 3, 673\u2013683 (2004).","journal-title":"Nat. Rev. Drug Disco."},{"key":"1332_CR15","doi-asserted-by":"publisher","first-page":"46067","DOI":"10.18632\/oncotarget.10022","volume":"7","author":"K Somers","year":"2016","unstructured":"Somers, K., Chudakova, D. A., Middlemiss, S. M. C., Wen, V. W., Clifton, M., Kwek, A. et al. CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements. Oncotarget 7, 46067\u201346087 (2016).","journal-title":"Oncotarget"},{"key":"1332_CR16","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","volume":"128","author":"SL Khaw","year":"2016","unstructured":"Khaw, S. L., Suryani, S., Evans, K., Richmond, J., Robbins, A., Kurmasheva, R. T. et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood 128, 1382\u20131395 (2016).","journal-title":"Blood"},{"key":"1332_CR17","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1038\/s41388-018-0666-5","volume":"38","author":"K Somers","year":"2019","unstructured":"Somers, K., Wen, V. W., Middlemiss, S. M. C., Osborne, B., Forgham, H., Jung, M. et al. A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. Oncogene 38, 3824\u20133842 (2019).","journal-title":"Oncogene"},{"key":"1332_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1128\/br.20.4.243-258.1956","volume":"20","author":"CI Bliss","year":"1956","unstructured":"Bliss, C. I. The calculation of microbial assays. Bacteriol. Rev. 20, 243\u2013258 (1956).","journal-title":"Bacteriol. Rev."},{"key":"1332_CR19","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/1087057114521867","volume":"19","author":"W Zhao","year":"2014","unstructured":"Zhao, W., Sachsenmeier, K., Zhang, L., Sult, E., Hollingsworth, R. E. & Yang, H. A new bliss independence model to analyze drug combination data. J. Biomol. Screen 19, 817\u2013821 (2014).","journal-title":"J. Biomol. Screen"},{"key":"1332_CR20","first-page":"e9","volume":"4","author":"CP Goswami","year":"2015","unstructured":"Goswami, C. P., Cheng, L., Alexander, P. S., Singal, A. & Li, L. A new drug combinatory effect prediction algorithm on the cancer cell based on gene expression and dose-response curve. Pharmacomet. Syst. Pharm. 4, e9 (2015).","journal-title":"Pharmacomet. Syst. Pharm."},{"key":"1332_CR21","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli, G. Y., Fornari, C., Wang, D., Mollard, S., Bramhall, J. L., Richards, F. M. et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics 32, 2866\u20132868 (2016).","journal-title":"Bioinformatics"},{"key":"1332_CR22","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1038\/nprot.2006.378","volume":"1","author":"I Rahman","year":"2006","unstructured":"Rahman, I., Kode, A. & Biswas, S. K. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat. Protoc. 1, 3159\u20133165 (2006).","journal-title":"Nat. Protoc."},{"key":"1332_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.bcp.2019.07.009","volume":"168","author":"CC Gana","year":"2019","unstructured":"Gana, C. C., Hanssen, K. M., Yu, D. M. T., Flemming, C. L., Wheatley, M. S., Conseil, G. et al. MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells. Biochem Pharm. 168, 237\u2013248 (2019).","journal-title":"Biochem Pharm."},{"key":"1332_CR24","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/s41375-019-0683-6","volume":"34","author":"K Somers","year":"2020","unstructured":"Somers, K., Evans, K., Cheung, L., Karsa, M., Pritchard, T., Kosciolek, A. et al. Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia. Leukemia. 34, 1524\u20131539 (2020).","journal-title":"Leukemia"},{"key":"1332_CR25","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-14-2300","volume":"21","author":"J Richmond","year":"2015","unstructured":"Richmond, J., Carol, H., Evans, K., High, L., Mendomo, A., Robbins, A. et al. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia. Clin. Cancer Res. 21, 1395\u20131405 (2015).","journal-title":"Clin. Cancer Res"},{"key":"1332_CR26","first-page":"671","volume":"2","author":"UR Kees","year":"2003","unstructured":"Kees, U. R., Ford, J., Watson, M., Murch, A., Ring\u0144er, M., Walker, R. J. et al. Gene expression profiles in a panel of childhood leukemia cell lines mirror critical features of the disease. Mol. Cancer Ther. 2, 671\u2013677 (2003).","journal-title":"Mol. Cancer Ther."},{"key":"1332_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bbacli.2014.06.003","volume":"1","author":"F Saletta","year":"2014","unstructured":"Saletta, F., Wadham, C., Ziegler, D. S., Marshall, G. M., Haber, M., McCowage, G. et al. Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clin. 1, 59\u201377 (2014).","journal-title":"BBA Clin."},{"key":"1332_CR28","doi-asserted-by":"crossref","unstructured":"Brown, P. Treatment of infant leukemias: challenge and promise. Hematology Am. Soc. Hematol. Educ. Program 2013, 596\u2013600 (2013).","DOI":"10.1182\/asheducation-2013.1.596"},{"key":"1332_CR29","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","volume":"376","author":"C Parker","year":"2011","unstructured":"Parker, C., Waters, R., Leighton, C., Hancock, J., Sutton, R., Moorman, A. V. et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 376, 2009\u20132017 (2011).","journal-title":"Lancet"},{"key":"1332_CR30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/bjh.14017","volume":"173","author":"B Burkhardt","year":"2016","unstructured":"Burkhardt, B., Mueller, S., Khanam, T. & Perkins, S. L. Current status and future directions of T-lymphoblastic lymphoma in children and adolescents. Br. J. Haematol. 173, 545\u2013559 (2016).","journal-title":"Br. J. Haematol."},{"key":"1332_CR31","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3389\/fped.2019.00368","volume":"7","author":"M Kuhlen","year":"2019","unstructured":"Kuhlen, M., Klusmann, J.-H. & Hoell, J. I. Molecular approaches to treating pediatric leukemias. Front Pediatr. 7, 356 (2019).","journal-title":"Front Pediatr."},{"key":"1332_CR32","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1002\/cncr.23395","volume":"112","author":"N Hijiya","year":"2008","unstructured":"Hijiya, N., Stewart, C. F., Zhou, Y., Campana, D., Coustan-Smith, E., Rivera, G. K. et al. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. Cancer 112, 1983\u20131991 (2008).","journal-title":"Cancer"},{"key":"1332_CR33","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1002\/ijc.27482","volume":"131","author":"C Conticello","year":"2012","unstructured":"Conticello, C., Martinetti, D., Adamo, L., Buccheri, S., Giuffrida, R., Parrinello, N. et al. Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. Int. J. Cancer 131, 2197\u20132203 (2012).","journal-title":"Int. J. Cancer"},{"key":"1332_CR34","doi-asserted-by":"publisher","first-page":"82200","DOI":"10.18632\/oncotarget.9413","volume":"7","author":"M Deng","year":"2016","unstructured":"Deng, M., Jiang, Z., Li, Y., Zhou, Y., Li, J., Wang, X. et al. Effective elimination of adult B-lineage acute lymphoblastic leukemia by disulfiram\/copper complex in vitro and in vivo in patient-derived xenograft models. Oncotarget 7, 82200\u201382212 (2016).","journal-title":"Oncotarget"},{"key":"1332_CR35","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1158\/0008-5472.CAN-13-2033","volume":"74","author":"W Fiskus","year":"2014","unstructured":"Fiskus, W., Saba, N., Shen, M., Ghias, M., Liu, J., Gupta, S. D. et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res 74, 2520\u20132532 (2014).","journal-title":"Cancer Res"},{"key":"1332_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4149\/gpb_2016043","volume":"36","author":"H Hwang-Bo","year":"2017","unstructured":"Hwang-Bo, H., Jeong, J. W., Han, M. H., Park, C., Hong, S. H., Kim, G. Y. et al. Auranofin, an inhibitor of thioredoxin reductase, induces apoptosis in hepatocellular carcinoma Hep3B cells by generation of reactive oxygen species. Gen. Physiol. Biophys. 36, 117\u2013128 (2017).","journal-title":"Gen. Physiol. Biophys."},{"key":"1332_CR37","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3892\/ol.2012.931","volume":"4","author":"O Zitka","year":"2012","unstructured":"Zitka, O., Skalickova, S., Gumulec, J., Masarik, M., Adam, V., Hubalek, J. et al. Redox status expressed as GSH:GSSG ratio as a marker for oxidative stress in paediatric tumour patients. Oncol. Lett. 4, 1247\u20131253 (2012).","journal-title":"Oncol. Lett."},{"key":"1332_CR38","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1182\/blood.V99.11.4100","volume":"99","author":"RB Lock","year":"2002","unstructured":"Lock, R. B., Liem, N., Farnsworth, M. L., Milross, C. G., Xue, C., Tajbakhsh, M. et al. The nonobese diabetic\/severe combined immunodeficient (NOD\/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 99, 4100\u20134108 (2002).","journal-title":"Blood"},{"key":"1332_CR39","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1182\/blood-2003-08-2911","volume":"103","author":"NL Liem","year":"2004","unstructured":"Liem, N. L., Papa, R. A., Milross, C. G., Schmid, M. A., Tajbakhsh, M., Choi, S. et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 103, 3905\u20133914 (2004).","journal-title":"Blood"},{"key":"1332_CR40","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1046\/j.1471-4159.2001.00395.x","volume":"78","author":"HM Geller","year":"2001","unstructured":"Geller, H. M., Cheng, K. Y., Goldsmith, N. K., Romero, A. A., Zhang, A. L., Morris, E. J. et al. Oxidative stress mediates neuronal DNA damage and apoptosis in response to cytosine arabinoside. J. Neurochem 78, 265\u2013275 (2001).","journal-title":"J. Neurochem"},{"key":"1332_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1158\/1535-7163.MCT-09-0952","volume":"9","author":"PJ Houghton","year":"2010","unstructured":"Houghton, P. J., Morton, C. I., Gorlick, R., Lock, R. B., Carol, H., Reynolds, C. P. et al. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric preclinical testing program. Mol. Cancer Ther. 9, 101\u2013112 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"1332_CR42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/leu.2016.165","volume":"31","author":"MN Cruickshank","year":"2017","unstructured":"Cruickshank, M. N., Ford, J., Cheung, L. C., Heng, J., Singh, S., Wells, J. et al. Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin. Leukemia 31, 40\u201350 (2017).","journal-title":"Leukemia"},{"key":"1332_CR43","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/j.1875-9114.1983.tb03277.x","volume":"3","author":"DE Furst","year":"1983","unstructured":"Furst, D. E. Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis. Pharmacotherapy 3, 284\u2013298 (1983).","journal-title":"Pharmacotherapy"},{"key":"1332_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","volume":"15","author":"C Roder","year":"2015","unstructured":"Roder, C. & Thomson, M. J. Auranofin: repurposing an old drug for a golden new age. Drugs R. D. 15, 13\u201320 (2015).","journal-title":"Drugs R. D."},{"key":"1332_CR45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10787-007-0021-x","volume":"16","author":"WF Kean","year":"2008","unstructured":"Kean, W. F. & Kean, I. R. Clinical pharmacology of gold. Inflammopharmacology 16, 112\u2013125 (2008).","journal-title":"Inflammopharmacology"},{"key":"1332_CR46","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.18632\/oncotarget.2113","volume":"5","author":"N Liu","year":"2014","unstructured":"Liu, N., Li, X., Huang, H., Zhao, C., Liao, S., Yang, C. et al. Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget 5, 5453\u20135471 (2014).","journal-title":"Oncotarget"},{"key":"1332_CR47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.redox.2015.06.004","volume":"5","author":"JE Hrabe","year":"2015","unstructured":"Hrabe, J. E., O\u2019Leary, B. R., Fath, M. A., Rodman, S. N., Button, A. M., Domann, F. E. et al. Disruption of thioredoxin metabolism enhances the toxicity of transforming growth factor \u03b2-activated kinase 1 (TAK1) inhibition in KRAS-mutated colon cancer cells. Redox Biol. 5, 319\u2013327 (2015).","journal-title":"Redox Biol."},{"key":"1332_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.132","volume":"5","author":"C Fan","year":"2014","unstructured":"Fan, C., Zheng, W., Fu, X., Li, X., Wong, Y. S. & Chen, T. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo. Cell Death Dis. 5, e1191 (2014).","journal-title":"Cell Death Dis."},{"key":"1332_CR49","first-page":"94","volume":"41","author":"TM Simon","year":"1981","unstructured":"Simon, T. M., Kunishima, D. H., Vibert, G. J. & Lorber, A. Screening trial with the coordinated gold compound auranofin using mouse lymphocyte leukemia P388. Cancer Res 41, 94\u201397 (1981).","journal-title":"Cancer Res"},{"key":"1332_CR50","doi-asserted-by":"publisher","first-page":"9118","DOI":"10.18632\/oncotarget.2361","volume":"5","author":"X Chen","year":"2014","unstructured":"Chen, X., Shi, X., Zhao, C., Li, X., Lan, X., Liu, S. et al. Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr\/Abl-dependent and -independent mechanisms. Oncotarget 5, 9118\u20139132 (2014).","journal-title":"Oncotarget"},{"key":"1332_CR51","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1182\/blood-2009-05-222711","volume":"115","author":"D Lewandowski","year":"2010","unstructured":"Lewandowski, D., Barroca, V., Ducong\u00e9, F., Bayer, J., Van Nhieu, J. T., Pestourie, C. et al. In vivo cellular imaging pinpoints the role of reactive oxygen species in the early steps of adult hematopoietic reconstitution. Blood 115, 443\u2013452 (2010).","journal-title":"Blood"},{"key":"1332_CR52","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.clinbiochem.2008.01.027","volume":"41","author":"V Battisti","year":"2008","unstructured":"Battisti, V., Maders, L. D., Bagatini, M. D., Santos, K. F., Spanevello, R. M., Maldonado, P. A. et al. Measurement of oxidative stress and antioxidant status in acute lymphoblastic leukemia patients. Clin. Biochem. 41, 511\u2013518 (2008).","journal-title":"Clin. Biochem"},{"key":"1332_CR53","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-16-2392","volume":"23","author":"L Jones","year":"2017","unstructured":"Jones, L., Richmond, J., Evans, K., Carol, H., Jing, D., Kurmasheva, R. T. et al. Bioluminescence imaging enhances analysis of drug responses in a patient-derived xenograft model of pediatric ALL. Clin. Cancer Res. 23, 3744\u20133755 (2017).","journal-title":"Clin. Cancer Res."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01332-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01332-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01332-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T08:04:58Z","timestamp":1675152298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01332-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7,6]]}},"alternative-id":["1332"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01332-x","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"assertion":[{"value":"29 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal studies were conducted with approval from the Animal Care and Ethics Committee of the University of New South Wales (Sydney, Australia).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"All data generated or analysed during this study are included in this published article and its  files.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research was supported by grants from the Anthony Rothe Memorial Trust, the Cancer Council NSW, the Tenix Foundation,\u00a0the Kids Cancer Alliance, the ISG Foundation, the National Health and Medical Research Council of Australia (NHMRC Fellowships APP1059804 and APP1157871) to R.B.L. and the Children\u2019s Leukaemia & Cancer Research Foundation (Perth, Western Australia) to U.R.K.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}